SynthesisSystematic reviews2026
MicroRNAs as potential prognostic biomarkers in acute lymphoblastic leukemia: a systematic review, meta-analysis, and bioinformatics study.
Synthesis in Systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAcute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by malignant transformation of lymphoid precursor cells. ALL prognosis differs considerably, especially between pediatric patients and adult patients, with poor response to therapy in adults. MicroRNAs (miRNAs), small non-coding RNAs that regulate the expression of genes, are possible cancer biomarkers that predict cancer prognosis. This systematic review and meta-analysis evaluates miRNAs as prognostic biomarkers in ALL and extends the findings through ceRNA network and single-cell RNA seq analyses of validated target genes. MATERIAL AND
methodsWe systematically searched PubMed, SCOPUS, and Web of Science (WOS) to identify studies that compared miRNA expression with the survival of ALL patients following the PRISMA guidelines. We reviewed these studies for their methodological quality, and hazard ratios (HRs) were extracted to examine miRNA expression and survival endpoints of overall survival (OS), disease-free survival (DFS), and relapse-free survival (RFS). We also applied single-cell RNA sequencing (scRNA-seq) and a competing endogenous RNA (ceRNA) network to study miRNA targets.
resultsmiR-335 showed a significant protective role with a pooled HR of 0.29 (95% CI, 0.12-0.68), miR-210 with a pooled HR of 0.22 (95% CI, 0.06-0.84), and miR-125b with a pooled HR of 0.39 (95% CI, 0.16-0.95) based on 22 examined studies involving 1974 patients. These miRNAs were correlated with improved OS, DFS, and RFS. We identified potential targets, whose functions were examined within key biological pathways through a ceRNA network. In various immune cell types, comparisons of B-ALL and T-ALL with normal cells showed that 36 and 98 target genes, respectively, were upregulated, while 21 and 19 genes were downregulated. Additionally, when comparing T-ALL to B-ALL cells, 70 target genes had increased expression, and 13 genes had decreased expression. Among all analyzed lineages, leukemic blast cells exhibited the most consistent and pronounced alterations in the expression of validated miRNA target genes, suggesting that blasts are the primary population influenced by these regulatory interactions in ALL.
conclusionThese findings support miRNAs as valuable prognostic biomarkers for ALL with potential for personalized therapy. The context-dependent role of these miRNAs highlights the need for confirmation through large, multicenter trials. The constructed ceRNA network provides useful insights into their regulatory mechanisms, opening new directions for therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.